Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 1;11(3):199-208.

How Do Donor-Recipient CMV Serostatus and Post-Hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?

Mohammad Vaezi  1 , Amir Kasaeian  1 , Maryam Souri  1 , Faeze Soufiyan  1 , Amir Shokri Boosjin  1 , Seyed Amin Setarehdan  1 , Kamran Alimoghaddam  1 , Ardeshir Ghavamzadeh  1
Affiliations

How Do Donor-Recipient CMV Serostatus and Post-Hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?

Mohammad Vaezi et al. Int J Hematol Oncol Stem Cell Res. .

Abstract

Background: This study evaluated CMV serostatus in donors and recipients of hematopoietic stem cell transplantation (HSCT) and its effects on CMV reactivation of patients and all aspects of CMV on HSCT outcomes. Materialsand Methods: Seven hundred and five adult acute leukemia patients (AML=408 and AML=297) who had undergone HSCT were included in this retrospective study. We categorized donor-recipient pairs in three risk groups: positive donors (D+) were studied as high-risk group, including either R+ or R-(n=485), R-D- as low-risk group (n=32) and R+D- as intermediate group (n=15). Results: There was no statistically difference in CMV reactivation among these risk groups (P=0.14).CMV infection rate was lower in R+D+ than R+D-(p=0.050). Multivariate analysis showed that patients developing CMV infection had lower overall survival (p=0.04, HR: 1.43, CI=1.00- 2.05) and higher non- relapse mortality (P=0.01, HR: 1.62, CI=1.11-2.38). Relapse rate did not change in CMV reactivated patients (P=0.94). Conclusion: The results of the study indicated that asCMV reactivation occurred more in R+D- patients compared to R+D+ ones, and was associated with inferior OS and higher NRM it could be suggested that in contrast to general belief, if the recipient is seropositive , seropositive donor is preferred to a seronegative one.

Keywords: Acute leukemia; CMV infection; CMV serostatus; Hematopoietic stem cell transplantation; Outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival of all patients according to CMV reactivation status (a),
Figure 1
Figure 1
relapse-free survival of all patients according to CMV reactivation status (b)
Figure 1
Figure 1
cumulative relapse incidence of all patients in relation to CMV reactivation (c)
Figure 1
Figure 1
and cumulative non-relapse mortality incidence in relation to CMV reactivation (d).
Figure 2
Figure 2
Cumulative incidence probabilities of CMV reactivation according to sero-status of recipients and donors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lönnqvist B, Ringdèn O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986;63(4):671–679. - PubMed
    1. Behrendt CE, Rosenthal J, BolotinE , et al. Donor and recipient CMV sero-status and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant. 2009;15(1):54–60. - PMC - PubMed
    1. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–1412. - PubMed
    1. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol. 2006;76(5):414–419. - PubMed
    1. Remberger M, Ringdén O. Survival after bone-marrow transplantation. Lancet. 2002;359(9309):888. - PubMed

LinkOut - more resources